Home » Topics » Cancer, BioWorld Science

Cancer, BioWorld Science
RSS

Ryvu submits CTA to begin phase I/II trial of RVU-120 in solid tumors

Jan. 5, 2021

BET inhibitor ODM-207 is safe in fist-in-human study in patients with solid tumors

Jan. 5, 2021

Ryvu Therapeutics identifies hSTING receptor agonists

Jan. 5, 2021

Ayala plans pivotal phase II/III RINGSIDE study of AL-102 in desmoid tumors

Jan. 5, 2021

Vivoryon Therapeutics patents meprin A inhibitors

Jan. 5, 2021

University of Alberta discovers ERCC1 inhibitors

Jan. 4, 2021

Medshine Discovery discloses new FGFR/VEGFR2 dual inhibitors

Jan. 4, 2021

ShanghaiTech University patents ALK-targeting PROTACs

Jan. 4, 2021

Preclinical evaluation of SPR-519, a novel dual PI3K-alpha and mTOR kinase inhibitor

Dec. 31, 2020

Mirati Therapeutics describes new polycomb protein EED inhibitors

Dec. 31, 2020

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 14, 2026.
AAIC 2026: Age of amyloid is being joined by time of tau
BioWorld
The Alzheimer’s Association International Conference (AAIC) is the world’s biggest dementia conference. And at the AAIC 2026 meeting, there is big buzz around...
Neurovalens granted FDA approval for PTSD therapy for US veterans
BioWorld
Veterans in the U.S. suffering from post-traumatic stress disorder (PTSD) now have access to Neurovalens Ltd.’s Modius Spero, a wearable neuromodulation device,...
News in brief
BioWorld Asia
BioWorld Asia briefs for July 14, 2026
Combination locked out in ATTR-CM? ‘Dead,’ expert says
BioWorld
The synergy – or lack of it – between knockdown drugs and stabilizers in treating transthyretin (TTR)-mediated amyloid cardiomyopathy (ATTR-CM) became one of the...